Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BEAM-201 |
| Trade Name | |
| Synonyms | BEAM 201|BEAM201 |
| Drug Descriptions |
BEAM-201 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD7 and to harbor mutations in TRAC, CD7, CD52, and PDCD1, which potentially induces killing of tumor cells expressing CD7 (Blood (2024) 144 (Supplement 1): 4838, NCI Drug Dictionary). |
| DrugClasses | CD7 Immune Cell Therapy 4 |
| CAS Registry Number | NA |
| NCIT ID | C200791 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BEAM-201 | BEAM-201 | 0 | 2 |